Heme

Advertisement
Andrew MorenoHemophilia | May 20, 2025
A preclinical mouse study showed hemostasis restoration, as well as use for active bleeding and internal bleeding prevention.
Andrew MorenoPNH | May 19, 2025
A novel complement-targeting agent shows impressive efficacy and safety without immunosuppression of the classical pathway.
Andrew MorenoVTE | May 16, 2025
Investigation of a HUNT Study cohort found elevated plasma MBL levels to be associated with increased risk for future VTE.
Andrew MorenoAnemia | May 16, 2025
Reactive oxygen species levels decreased and patients with evident bone marrow failure showed hematological response.
Andrew MorenoVTE | May 19, 2025
A cohort study of extended-phase anticoagulation following acute management was performed in the phase III EINSTEIN Jr trial.
Melissa BadamoHemophilia | May 13, 2025
Fidanacogene elaparvovec gene therapy is a safe and effective treatment for patients with hemophilia B, research shows.
Andrew MorenoPolycythemia Vera | May 12, 2025
The agent targets abnormal gene expression in order to control the excessive cell proliferation that occurs in PV.
Andrew MorenoMDS | May 12, 2025
A study has explored the clinical impact of both mutation-based and non-mutation-based p53 dysfunction in MDS.
Andrew MorenoMDS | May 9, 2025
Preclinical models show significant efficacy in combos against AML cell lines with FLT3, KMT2A, NPM1, and TP53 mutations.
Melissa BadamoSickle Cell Disease | May 7, 2025
Compared with placebo, crizanlizumab has superior safety and comparable efficacy in patients with sickle cell disease.
Andrew MorenoHematology | May 7, 2025
Investigators used two AI-driven tools to analyze multiple myeloma therapies' clinical literature and patent information.
Melissa BadamoMDS | May 6, 2025
Mice treated with the novel approach had a “significantly lower tumor burden” compared with mice that received controls.
Andrew MorenoHematology | May 5, 2025
The two specific combinations recently approved by the MHRA in the UK also have a BLA currently under review at the FDA.
Andrew MorenoHematology | May 5, 2025
The agent produced favorable safety results, had no dose-limiting toxicities, and did not interfere with CAR T-cell therapy.
Paul George, MD, PhDSickle Cell Disease | May 8, 2025
The study led by Paul George, MD, PhD, also highlights the importance of patient regimen adherence to secure these benefits.
Andrew MorenoHemophilia | April 30, 2025
Approval was based on data from phase 3 studies in the ongoing ATLAS clinical development program.
Andrew MorenoSickle Cell Disease | April 29, 2025
The findings coincide with patient reports of experiencing increased vaso-occlusive episodes during menses.
Adrián Mosquera Orgueira, MD, PhDMyelofibrosis | April 25, 2025
Adrián Mosquera Orgueira, MD, PhD, spoke of his team's study into machine learning tools for improving risk stratification.
Andrew MorenoHemophilia | April 23, 2025
The Clinical Practice Guidance document issued by the EHA, ISTH, EAHAD, and ESO addresses both hemophilia A and B.
Melissa BadamoSickle Cell Disease | April 22, 2025
The Foundation for Sickle Cell Disease Research will evaluate VAS-101 in a phase 1 clinical study.
Advertisement